Takeda Pharmaceutical Co Ltd - FY2025 Financial Summary
Business Context and Reporting Period
This filing (Form 6-K) presents the financial results for Takeda Pharmaceutical Co Ltd for the fiscal year ended March 31, 2025 (FY2025), and the fourth quarter (January–March 2025). The document includes reported results under IFRS and non-IFRS "Core" measures, which exclude amortization, impairment, and other non-recurring items to reflect underlying business performance. The filing also provides a full-year forecast for FY2026 issued on May 13, 2026.
Key Financial Metrics (FY2025)
| Metric | FY2025 Reported (Billion JPY) | FY2025 Core (Billion JPY) | YoY Change (CER %) |
|---|---|---|---|
| Revenue | 4,505.7 | 4,505.7 | -2.6% |
| Operating Profit | 408.8 | 1,172.5 | 14.5% (Reported) / -0.9% (Core) |
| Net Profit (Attributable to Owners) | 191.8 | 814.1 | 65.8% (Reported) / 2.9% (Core) |
| Basic EPS (JPY) | 121.75 | 517 | 66.2% (Reported) / 3.1% (Core) |
| Adjusted Free Cash Flow | 684.5 | N/A | -11.0% vs FY2024 |
| Adjusted Net Debt | (3,817.6) | N/A | N/A |
| Adjusted Net Debt / Adjusted EBITDA | 2.6x | N/A | Improved from 2.8x in FY2024 |
Q4 2025 Highlights: Reported operating profit was a loss of JPY 13.6 billion, compared to a loss of JPY 74.9 billion in Q4 2024. Core operating profit for Q4 was JPY 200.9 billion, a 15.1% increase on a constant exchange rate basis.
Material Changes vs. Prior Period
- Revenue: Reported revenue declined 2.7% on an actual exchange rate basis and 2.6% on a constant exchange rate (CER) basis, driven by lower sales of products including ENTYVIO and PDT products, partially offset by favorable FX impacts.
- Profitability: Reported operating profit increased 19.3% (AER) to JPY 408.8 billion, primarily due to a significant reduction in impairment losses on intangible assets (down 36.0% to JPY 129.3 billion) and lower amortization. However, Core Operating Profit declined 0.9% (CER) to JPY 1,172.5 billion.
- Net Profit: Reported net profit surged 77.7% to JPY 191.8 billion, driven by lower impairment charges, higher finance income (gains on FX derivatives), and an improved effective tax rate due to the reassessment of deferred tax asset recoverability.
- Cash Flow: Adjusted Free Cash Flow decreased 11.0% to JPY 684.5 billion, impacted by higher acquisitions of intangible assets (JPY 234.9 billion vs JPY 147.0 billion in FY2024) and lower proceeds from the sale of shares in associates.
Guidance, Outlook, and Risks
FY2026 Forecast (Issued May 13, 2026):
- Revenue: Forecast at JPY 4,640.0 billion (+3.0% YoY), driven by FX tailwinds and new product launches offsetting loss-of-exclusivity (LOE) impacts.
- Operating Profit: Forecast at JPY 420.0 billion (+2.7% YoY). Core Operating Profit is expected to be flat (-1.1% YoY) due to higher restructuring expenses (forecast JPY 170.0 billion vs JPY 70.8 billion actual in FY25) and increased R&D spend.
- Net Profit: Forecast at JPY 166.0 billion (-13.4% YoY), reflecting higher restructuring costs and a lower effective tax rate assumption.
- Adjusted Free Cash Flow: Forecast range of JPY 650.0 to 750.0 billion, broadly in line with FY2025.
Key Risks and Contingencies:
- Restructuring Costs: Significant increase in restructuring expenses in FY2026 related to the transformation program.
- FX Sensitivity: The company remains sensitive to currency fluctuations; a 1% depreciation of the yen against the USD is estimated to increase FY2026 revenue by JPY 206.1 billion but decrease operating profit by JPY 4.2 billion.
- Product Lifecycle: Continued revenue pressure from LOE products, partially mitigated by new launches.
Investor Verification Checklist
- Impairment Volatility: Verify the sustainability of the reported profit surge, which was heavily influenced by a JPY 31.9 billion impairment on ALUNBRIG and lower overall impairment charges compared to prior years.
- Restructuring Execution: Monitor the execution of the transformation program, as FY2026 forecasts assume JPY 170.0 billion in restructuring expenses, a significant increase from FY2025 actuals.
- Core vs. Reported Divergence: Analyze the widening gap between Reported and Core metrics; while Reported EPS grew 66%, Core EPS grew only 3.1%, indicating that non-recurring items (amortization/impairment) are masking underlying operational trends.
- Cash Flow Quality: Review the decline in Adjusted Free Cash Flow (-11%) driven by increased intangible asset acquisitions and reduced proceeds from associate sales.
- FX Assumptions: Confirm the validity of the FY2026 FX assumptions (USD/JPY 156, EUR/JPY 182) given the sensitivity of revenue and profit to currency movements.